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Background: Currently, there is a paucity of data concerning the long-term outcomes, educational placement and
quality of life of children implanted with hearing devices from large and representative samples of the population.
To address this concern, a large, prospective, multicentre, multinational patient-outcomes registry for paediatric
recipients of implantable hearing devices was developed. The benefits of this registry, its approach and methodology
are described.
Methods/Design: The Cochlear™ Paediatric Implanted Recipient Observational Study (Cochlear P-IROS) is a
prospective international patient-outcomes registry for children who are implanted in routine clinical practice
with one or more hearing devices. The study aims to collect data on patient comorbidities, device use, auditory
performance, quality of life and health-related utilities, across different types of implantable hearing devices from a
range of manufacturers. Patients will be evaluated with a set of standardised and non-standardised questionnaires prior
to initial device activation (baseline) and at six-monthly follow-up intervals up to 24 months and annually thereafter.
The Cochlear P-IROS utilises a secure web interface to administer electronic case report forms to clinicians and
families of implanted children. The web interface is currently available in five languages: English, Japanese,
Korean, Mandarin and Russian. The interface also provides printable versions of the case report forms translated
into 22 local languages for collection of data prior to entry online; additional languages may be added, as required.
Participation in the Cochlear P-IROS registry is investigator-driven and voluntary. To date, the Cochlear P-IROS has
recruited implant clinics across Australia, China, India, Indonesia, Turkey and Vietnam. The registry also aims to
recruit multiple clinics in Cuba, Israel, Japan, Malaysia, Singapore, South Africa, South Korea and Russia.
Discussion: The use of a registry such as the Cochlear P-IROS will generate valuable data to support research
interests of academics and clinicians around the globe. The data generated will be relevant for a wide range of
stakeholders including regulators, payers, providers, policy makers, patients and their families, each with a different
perspective for the acceptance and adoption of implantable hearing devices for the treatment of hearing loss.
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Hearing loss affects an estimated 5.3% of the world’s
population that amounts to approximately 360 million
people, of which 9% are children [1]. The global preva-
lence of hearing impairment, defined as an average hear-
ing loss of 35 decibels hearing level (dBHL) or more in
the better ear, is estimated at 1.4% in children aged 5–14
years [2]. The global prevalence of severe-to-profound
hearing loss, defined as hearing loss of 61 dBHL or
greater in the better ear [3], is estimated at 4.8% and
6.4% among children aged 0–1 years and 1–4 years,
respectively (personal communication, G. Stevens, WHO).
The prevalence of hearing loss varies across demographic
regions and is associated with socioeconomic status,
local risk factors such as exposure to infectious dis-
eases, different cultural practices such as consanguinity
and other causes also influenced by regional and geo-
graphic factors [2,4]. Prevalence of hearing impairment
is greater in regions of low and middle income and is
positively related to age and male sex [2].
The gold standard interventions available for treating
patients with a permanent hearing impairment include
cochlear implants and bone conduction implants. Cochlear
implantation is the recommended treatment for children
presenting with a permanent bilateral sensorineural hearing
loss [5,6]. This impairment may range from moderate in
the low frequencies sloping towards severe to profound
in the high frequencies. Bone conduction implants may
be prescribed for children with an ongoing permanent
conductive hearing loss, mixed hearing loss or single-sided
sensorineural hearing loss [7]. While these interventions
remain the most widely used, in some jurisdictions where
relevant regulatory requirements are satisfied, other
implantable technologies such as middle ear implants
or auditory brain stem implants may be recommended
for children whose hearing loss is primarily due to
malformations or injuries to the middle ear or the
auditory nerve.
Large investments into research and development as
well as over 30 years of clinical experience have estab-
lished that cochlear implants and bone conduction
implants are safe and clinically effective. This resulted
in the expansion of the candidacy criteria to include
very young children [8,9]. In the paediatric population,
surgical risk from cochlear implantation is low and
comparable to rates reported from general surgery for
children [9-13]. A recent report inferred a major com-
plication rate of 1.6% for children implanted bilaterally
whose age ranged from six months to 18 years [14].
For bone conduction hearing implants in children,
however, a number of factors, including the thickness of
cortical bone, bone quality and skin thickness influence
the surgical complication rate [15,16]. Compromised or
soft bone with thickness <2.5 mm may present ascontraindications for these devices in very young children.
A recent meta-analysis reporting complications associated
with bone conduction implants from various under-
powered studies suggested rates in children ranging from
0.0% to 14.3%, 5.6% to 44.4% and 0.0% to 44.4% for
osseointegration failure, implant infection and revision
surgery , respectively [17].
Despite advancements in technology, there are cur-
rently few ‘best practice’ guidelines available to help
inform professionals about implantable hearing devices
[18]. Instead, there are a myriad of individual implant
program protocols, each with variant indications devel-
oped over time, based on clinician expertise, published
literature and services unique to each jurisdiction. The
available data to support uniform evidence-based
practice remains low and heterogeneous with relatively
few studies being carried out in large and representa-
tive population samples with the purpose of collecting
long term patient-related outcomes [17].
The National Institute of Health and Care Excellence
(NICE) health technology appraisal into the clinical and
cost-effectiveness of cochlear implants in adults and
children, reviewed the body of evidence of cochlear
implants with the consideration of expert opinion. The
final appraisal document was published in February
2009 highlighting recommendations for clinical practice in
the UK [19]. The NICE recommendations included the
provision of simultaneous bilateral CI to children born
deaf, adventitiously deaf or those newly diagnosed with
severe-to-profound bilateral hearing impairment. The
report also highlighted deficiencies in the available evi-
dence, including difficulties in making comparisons
due to the heterogeneity in measures and protocols,
the absence of sufficiently long-term observation pe-
riods, the absence of benefits observed in daily circum-
stances and in the quality of life for the implanted
child. To this end, the authors of the NICE report
noted that more large scale studies are needed that
prospectively follow-up patients for longer time
periods, using standard measures of outcomes, and
collecting full information of known covariates of post-
implantation outcomes such as speech production,
speech recognition and quality of life.
In response, a national audit was set up through colla
boration of the cochlear implant programmes throughout
the United Kingdom (UK). The UK national audit of
paediatric bilateral cochlear implantation, which began
in January 2010 and ended in December 2012, is one of
the largest non-randomised prospective, observational
studies exploring hearing outcomes in children with a
permanent bilateral sensorineural hearing loss treated
with cochlear implants [20]. The data collected in-
cluded: listening ability, speech recognition, speech pro-
duction, sound localisation, acquisition of vocabulary,
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implant surgery. Although the report from the audit
showed encouraging results for bilaterally implanted
children when considering hearing gains as well as accept-
ably low rates of adverse events, the study did not measure
quality of life or other humanistic measures such as access
to services, educational placement, literacy, numeracy
or social inclusion, which are of interest to payers and
policy makers.
With continued pressures on healthcare systems and
budgets, there is now an increasing demand for evidence-
based research that demonstrates an intervention is
effective in the real-world environment across large and
diverse populations. A common measure of utility such as
‘quality of life years gained’ is often requested by Health
Technology Assessment (HTA) authorities, governments
and payers so that a rational allocation of scarce resources
may be achieved across the spectrum of healthcare
interventions.
Many types of impairment have the potential to impact
an individual’s everyday life, although the degree of impact
may vary from one individual to another, independent of
the severity of impairment [21]. Measuring not only the
hearing-performance benefit of implantable hearing de-
vices but also their impact on the individual’s everyday
life (i.e., their quality of life) is, therefore, important.
The WHO defines quality of life as an individual’s per-
ception of their position in life in the context of the cul-
ture and value systems in which they live and in relation
to their goals, expectations, standards and concerns
[22]. Despite the availability of a number of instruments
to measure an individual’s health-related quality of life,
such as the EuroQoL and the SF-36, these remain limited
in their sensitivity to hearing loss and their appropriate-
ness for assessment of very young implanted children
via parent proxy [23,24].
Several authors have recommended the use of a stan-
dardised, electronic patient registry for the collection of
a homogeneous set of data for cochlear implant recipi-
ents [25,26]. Others have acknowledged that the imple-
mentation of an electronic registry across large and
diverse recipient populations is both costly and com-
plex [27]. Prospective, longitudinal patient outcome
registries have also been proposed as an effective means
to address the increasing demand for data on patient-
related benefits of medical devices by the United States
Food and Drug Administration (FDA) [28,29].
As a step towards generating a consistently collated
and reported dataset on children implanted with hearing
devices, the Cochlear Paediatric Implanted Recipient
Observational Study (Cochlear P-IROS) was developed.
This global, prospective, observational study provides for,
and facilitates, a more unified approach for the assessment
of patient outcomes cross-culturally, in a structured,sustainable and easily accessible format. The Cochlear
P-IROS study design is based on the primary hypotheses
of intra-subject improvements in auditory performance
of children using implantable hearing devices across
diverse language and cultural settings. A consistent set
of questionnaire-based assessments and patient-related
information will be collected via a web-based electronic
data capture (EDC) platform.
The purpose of this paper is to introduce the design
and methodology of the Cochlear P-IROS registry. The
objectives of the study are threefold:
a) To evaluate the longitudinal improvements in
auditory performance with implantable hearing
devices in children using standardised
questionnaires.
b) To provide statistically significant data to support
patient management decisions at the clinical,
regulatory, payer and policy level.
c) To compare the patient-related or humanistic
benefits such as educational attainment, quality of
life and patient satisfaction resulting from use of




A prospective, longitudinal, observational study that will
be implemented globally across multiple hearing implant
centres on a voluntary basis. The study will be imple-
mented through a secure, web-based, registry platform
that enables collection of response data from clinicians
and patient proxy via electronic case report forms
(eCRFs) at consistent time intervals, thus enabling the
comparison of repeated measures over time.Population
The Cochlear P-IROS will enrol infants and children up
to age 10 years, at the time of intervention. Children
(referred to as ‘patients’), may receive any brand of regu-
latory approved implantable hearing device including
any type of cochlear, bone conduction, electroacoustic or
other implantable hearing device. If required, the Cochlear
P-IROS platform also permits the capture of data from
patients implanted at age 10 years or above, to address
the growing trend for intervention in older children with
an acquired or progressive hearing loss [30]. Additional
questionnaires appropriate for this age bracket have been
included for completion by these individuals' proxies. Pa-
tients above age 10 years may also be entered into the
Cochlear IROS platform, a corresponding registry plat-
form already implemented for adult patients.
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study are as follows:
Inclusion criteria:
1. Newly implanted prelingual and perilingual patients
less than age 10 years, prior to the first time the
hearing implant system is activated by the fitting of
the sound processor.
2. Unilateral, bilateral or bimodal users of cochlear
implants, electroacoustic devices, bone conduction
implants, or other implantable hearing systems.
3. Parent/caregiver and/or patient are cognitively able
to respond to self-administered/proxy assessment
scales and willing to participate and sign the Patient
Informed Consent form.
Exclusion criteria:
1. Patients with previous hearing implant experience.
This includes all brands and types of cochlear, bone
conduction, electroacoustic and auditory brainstem
implant systems.
Study period
The Cochlear P-IROS registry will be available for
clinics on a voluntary basis for monitoring the long-
term progress of patients and sub-groups of patients
using hearing devices. The recruitment of study sites is
ongoing. Any implant clinic may join the Cochlear
P-IROS to gather longitudinal data for newly implanted
and enrolled patients at their discretion. For patients
enrolled, baseline registration is scheduled post-implant,Table 1 Cochlear P-IROS evaluation schedule illustrating elect
evaluation time-point
Electronic case report form
Clinician baseline form
Clinician follow-up form
Implant recipient baseline form
Implant recipient follow-up form
Children using Hearing Implants Quality of Life (CuHI-QoL) Questionnaire
Health Utility Index Mark III (HUI3)**
Categories of Auditory Performance-II (CAP-II) Questionnaire
Speech Spatial Qualities (SSQ) Parents Version Questionnaire (SSQ-P)
Speech Spatial Qualities (SSQ) Standard Version**
Unaided hearing thresholds form
Aided hearing thresholds form
End of study form
Notes:
**Will be available in Cochlear P-IROS if the patient is >10 years at time of implanta
1. ■ represent required data capture (i.e., minimum dataset).
2. □ represent optional data capture.
3. – indicates that data capture is not relevant/required.which may ideally be at any time after surgery and prior to
the first time the hearing implant system is switched on by
the fitting of the externally worn sound processor. Typic-
ally, activation occurs at two to four weeks post-operation.
As illustrated in Table 1, suggested follow-up evaluations
may be recorded at six months, 12 months, 18 months,
24 months, and annually thereafter for up to five years,
ideally in parallel to routine clinical visits. Once a clinic
voluntarily enrols a patient, it is assumed that adherence
to the study protocol will occur, including a submission of
their respective follow-up data for a minimum of two
years post-surgery. Further evaluation of the patient, in
the longer term, will remain optional. As the registry is
entirely investigator-driven, the clinician is responsible for
counselling and ensuring that the patient and their family
are sufficiently motivated to participate in the study, long-
term, while maintaining the decision for their participation
as voluntary.
Ethical considerations
The Cochlear P-IROS will be conducted according to
the guidelines established in the Declaration of Helsinki
(Fortaleza, 2013) [31]. All study investigators, as well as
the sponsor, are bound to follow obligations outlined in
the Declaration of Helsinki and the ISO 14155:2011, the
international standard regarding good clinical practice
for clinical investigations of medical devices for human
subjects [32]. The guidance includes the design, conduct,
record and report, including protection of patient priv-
acy for all clinical investigations performed in human
subjects [31]. According to the standard, an investigatorronic case report forms used against the recommended
Evaluation time point (Months post-implant)
0 6 12 18 24 36 48 60
■ - - - - - - -
- ■ ■ ■ ■ □ □ □
■ - - - - - - -
- ■ ■ ■ ■ □ □ □
■ ■ ■ ■ ■ □ □ □
■ ■ ■ ■ ■ □ □ □
■ ■ ■ ■ ■ □ □ □
□ □ □ - □ □ □ □
□ □ □ - □ □ □ □
□ □ □ □ □ □ □ □
□ □ □ □ □ □ □ □
To be completed once when patient exits study
tion.
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team designated and supervised by the principal
investigator (referred to as the ‘chief investigator’ in the
Cochlear P-IROS) at an investigational site, to perform
critical procedures or to make important decisions relat-
ing to the clinical study. The sponsor is defined as the
organisation taking responsibility and liability for the
initiation or implementation of the clinical study. Cochlear
Limited is the sponsor for the Cochlear P-IROS (refer to
Table 2).
All sites wishing to participate in the Cochlear P-IROS
must approach their responsible Ethic Committee (EC)
or Investigational Research Board (IRB) for their formal
opinion as to whether EC or IRB approval is required, or
if a waver may be provided prior to commencement of
any data collection. While the need for EC approval may
be wavered, pending local or national jurisdictions, any
centre planning to publish their data is recommended
to obtain ethics committee approval, which is often
requested as a pre-requisite for manuscript acceptance
by scientific journal editors and reviewers.
Presently, the Cochlear P-IROS has gained approval
from the ethics advisory board of Hear and Say (Brisbane,
Australia), Peking University Third Hospital (Beijing,
China) and the Istanbul University, Faculty of Medi-
cine, (Istanbul, Turkey). In Turkey, one ethics approval
from a local clinic was acceptable nationally; therefore
ethics approval was waived at Marmara University
Hospital (Istanbul, Turkey) and Osmangazi University
Hospital (Eskisehir, Turkey). Ethics Committee ap-
proval was not required at the following study sites at
the time of registration with the Cochlear P-IROS;
First Affiliated University of Anhui Medical University
(Hefei, China), Peking Union Medical College Hospital
(Beijing, China), Saket City Hospital (New Delhi, India),
Shruti ENT Hospital and Cochlear Implant Centre (Surat,
India), Salemba Satu Medika (Jakarta, Indonesia) and
Shandong Provincial Hospital (Jinan, China).
Patient informed consent
Patient informed consent is compulsory, and must be
obtained in writing from a parent, guardian or the care-
giver with legal responsibility for the implanted child,
prior to the child’s enrolment in the registry. This is
required after the patient is implanted, when the deci-
sion for device type and configuration has already been
made, to ensure the decision to participate in the regis-
try remains independent of the type and brand of the de-
vice implanted. A Cochlear P-IROS Patient Information
Sheet will be provided to each participating family in their
local language by the authorised investigators (refer to
Table 2) who are responsible for obtaining patient consent
and explaining the purpose of the study, why they have
been chosen to take part in the study, potential advantagesand disadvantages of participation, and what happens once
the research study ends. Authorised investigators are also
advised to review their local Patient Consent Forms to
ensure that the information collected through the registry
is in alignment with the terms and conditions for research
in their clinic.
Evaluation measures
The Cochlear P-IROS registry addresses the need for
representative and uniform data concerning the clinical
and humanistic benefits of patients using implantable
hearing devices as medical evidence. Careful consider-
ation was given to the selection of evaluation measures
and their administration with respect to age at time of
implantation of potentially recruited patients up to age
10 years. Factors considered included achieving a balance
between subjective and objective measures, assessments of
auditory performance that catered for the development as
well as the range of listening and communication skills of
the patients, suitable for administration via investigator
and parental proxies, and suitable for translation and
cultural adaptation [33].
The Cochlear P-IROS provides the guidelines and the
evaluation tools for administration of both standardised
and non-standardised sponsor-generated questionnaires
for clinicians and parents/caregivers of patients using
implantable hearing devices. Sponsor-generated ques-
tionnaires for clinicians and parents/caregivers were
developed following a thorough review of the published
literature for confounders of outcomes and in consult-
ation with published researchers in the hearing implant
field to address gaps in existing assessment of humanis-
tic factors in children [34-39]. Through their repeated
use in studies such as the Cochlear P-IROS, the collec-
tion of response data for these new questionnaires may
support their standardisation over time. In addition to
these subjective measures, pure tone averages of the
implanted and non-implanted ears have been included.
A summary of the full set of evaluation tools used in the
study is provided in Table 3.
Evaluation forms for the clinician
Clinician baseline form This form serves for the regis-
tration of the patient at the baseline evaluation and fo-
cuses on the collection of patient profile specifics and
their hearing history. It also collects information related
to the implanted device/s and the external sound proces-
sors to be used, as well as any clinical details such as
patient comorbidities, surgical approach, aetiology of the
disease and hearing history. Questions in relation to num-
ber of weeks of gestation, physical balance, dizziness, com-
monly used mode of communication, physical and mental
impairment, and other comorbidities and syndromes were
Table 2 User roles by access levels to the Cochlear P-IROS and functionality
Investigator Sponsor Service provider





Accepts terms of registry agreement √ - - - - - -
Obtain patient consent √ √ √ - - - -
Enter patient data √ √ √ √ - - -
Edit patient data √ √ √ √ - - -
View and download patient data √1 √1 √2 - √ 3 √4 √5
Transfer patient √ - - - - - -
Notified of new clinics and patients - - - - √ √ √
Number of users permitted per study site 1¥ ≥1 ≥1 ≥1 NA NA NA
NA: Not applicable.
Notes:
√ indicates required functionality.
- indicates prohibited functionality.
* The term clinician used throughout the manuscript refers to the responsibilities of the: Chief Investigator, Unlimited Investigator and Limited Investigator. The Study Nurse user profile will be applicable for data entry
purposes only and is, therefore, not typically a clinician.
¥ Each site requires one Chief Investigator, as a maximum. There is no upper limit to the number other investigators or study nurses that may be involved.
1. Can view/download data of all site’s patients.
2. Can view/download data of the investigator’s patients only.
3. Can view/download data of patients at the global level.
4. Can view/download data of patients at the national level.






















Table 3 A description of evaluation tools used in the Cochlear P-IROS for longitudinal assessment of speech perception, language development, auditory
performance, educational placement, quality of life, device use and associated clinical and demographic covariates
Construct Evaluation tool Reference Categories of data collected Scales used
Clinical/surgical information,
device-related data
Clinician Baseline Form Sponsor generated forms • implantable hearing device details -
Clinician Follow-up Form • surgical approach used
• general medical and hearing history
• source of referral
• source of funding for implantation
• compliance to therapy/rehabilitation
• clinician satisfaction with progress
Patient demographics, hearing
history and habilitation
Implant Recipient Baseline Form Sponsor generated forms • hearing-aid use
• communication mode
• type of habilitation
• patient’s educational placement
Implant Recipient Follow-up Form
• family composition
• socio economic variables
• parent/carer satisfaction with child’s progress
Auditory Performance Categories of Auditory Performance-II
(CAP-II) Questionnaire
[41] Child’s functional use of audition in
everyday situations
CAP–II score over 10-
point scale (Range 0 to 9)
Self-reported hearing function Speech Spatial Qualities– Parents’
Version (SSQ-P) Questionnaire
[38] Auditory disability across a wide variety of domains,
representing hearing in the everyday situations.
SSQ-P score over 3 domains
Speech Spatial Qualities (SSQ) – optional
for children 10 years or older
[36] Auditory disability across a wide variety of domains,
reflecting the reality of hearing in everyday situations.
SSQ score over 3 domains
Quality of life Children using Hearing Implants
Quality of Life Questionnaire (CuHI-QoL)
Sponsor generated form
Additional file 1
The impact of hearing implants on the: CuHI-QoL score over 3 domains
• quality of life of very young children,
• their parents’ expectations and
• their immediate family.
Health Utility Index Mark III (HUI3) –
optional for children 10 years or older
[48] The HUI3 includes eight attributes of health status: Health Utility Score






























Table 3 A description of evaluation tools used in the Cochlear P-IROS for longitudinal assessment of speech perception, language development, auditory
performance, educational placement, quality of life, device use and associated clinical and demographic covariates (Continued)
Unaided Hearing Threshold Unaided Hearing Threshold Form Sponsor generated form • Otoacoutsic Emissions (OAE) and Auditory Brainstem
Responses (ABR) may be recorded for very
young children.
• Unaided air-conduction hearing-threshold
measurements, pre- and post-implantation.
• Unaided bone-conduction hearing threshold
measurements, pre- and post-implantation.
Aided Hearing Threshold Aided Hearing Threshold Form Sponsor generated form • Aided air-conduction thresholds, pre and
post-surgery.
-
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tions on sources of referral and funds for implantation.
Clinician follow-up form This form corresponds to the
Clinician Baseline Form and is to be completed at each
subsequent follow-up. The questions are designed to
capture any changes that may have occurred since the
previous evaluation interval, including details of any
new implanted device/s and external sound processors.
Additionally, it collects information regarding compli-
ance to device use and therapy, the quality of family’s
participation in the child’s habilitation and the clini-
cian’s satisfaction with the patient’s progress [40].
The Categories of Auditory Performance – II
(CAP-II) The CAP is a widely-used, simple, language-
independent, and culturally adaptable measure of audi-
tory performance suitable for assessment in children of
all ages, including patients less than age four years [37].
The majority of the literature, to date, has used the
eight-point hierarchy rating scale of the CAP that as-
sesses a child’s functioning in everyday situations. It
covers a range of auditory performance abilities and also
takes into consideration the different developmental
rates of children. The CAP consists of a nonlinear, hier-
archical scale with a score 0 equating to the lowest skill
of, “no awareness of environmental sounds”, and a score
7 corresponding to the highest skill of, “use of telephone
with a known listener”. Evidence shows a ceiling effect
of the CAP as it does not address the more complicated
listening skills now achievable with cochlear implants
and other hearing devices, particularly when used in bi-
lateral configurations. As such, an extension of the CAP
was introduced in 2010, called the CAP-II [41].
The CAP-II, when compared to the CAP, adds two
additional higher-level auditory skill categories to the
original scale. As such, the CAP-II is a more sensitive
measure of the range of auditory skills in hearing im-
paired children. Hence, the CAP-II was selected for use in
the Cochlear P-IROS, to assess the patient-related auditory
benefits arising from the use of implantable hearing de-
vices in the unilateral and bilateral configuration com-
pared with the pre-operative listening condition [14,20].
Unaided hearing thresholds form This evaluation form
collects unaided hearing thresholds measured through
behavioural audiometry in the sound-field or via head-
phones for air-conduction and bone-conduction hearing
thresholds performed routinely in the clinic. Thresholds
for the speech frequency range 250 Hz 500 Hz, 1000 Hz,
2000 Hz, 4000 Hz and 8000 Hz are desired for measure
and record for each ear. This form is used at the baseline
visit following registration of the patient online, to capture
the pre-implanted hearing thresholds for the patient.Subsequently post-operative hearing thresholds routinely
measured for bone and air conduction in each ear may be
recorded at follow-up intervals, using this form, as desired.
For infants, where pure tone audiometry is not applicable,
Otoacoutsic Emissions (OAE) and Auditory Brainstem
Responses (ABR) may be recorded. Repeated hearing
threshold measures may be compared over time to assess
their stability following treatment.
Aided hearing thresholds form This evaluation form
collects aided hearing threshold levels for warble tones for
each ear as routinely measured at the clinic through
behavioural audiometry in the sound field, pre-operatively
using a hearing aid and post-operatively using an implant-
able hearing device. Record of sound-field, aided hearing
thresholds for warble tones in individual ears, where
feasible, for the frequencies 250 Hz, 500 Hz, 1000 Hz,
2000 Hz, 4000 Hz and 8000 Hz, is desired at baseline
and at follow-up intervals, six monthly intervals up to
two years and annually up to five years post surgery.
Repeated aided thresholds are compared over time and
to unaided thresholds at the same time interval for
determination of objective functional threshold gains.
End of study form This form is completed for each
registered patient upon his or her departure from the
registry. This may be either at the completion of the
prescribed set of evaluations (e.g., two, three, four, or
five years post-implant) or prematurely at the request of
the clinician or parent/caregiver or following an event
requiring removal of the patient from further review.
The clinician is asked to record the reason for prema-
ture termination of the review and subsequent data
collection and date of exit from the study for each patient
enrolled in the study.
Evaluation forms for the parent/caregiver
Implant recipient baseline/follow-up forms These forms
are self-administered by the parent/caregiver at base-
line and follow-up intervals to collect complementary
patient-specific data to that gathered in the Clinician
Baseline/Follow-up forms. They are designed to gather
basic hearing experience information and patient char-
acteristics, including hearing aid use prior to and after
the surgery, age at implantation, familial socio-economic
factors, educational placement and communication mode,
that may influence clinical and humanistic outcomes.
Children using Hearing Implants Quality of Life
(CuHI-QoL) This is a new Quality of Life instrument
designed for this study, developed to assess quality of life of
patients using implantable hearing devices via parent proxy
(A copy of this questionnaire is available electronically)
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plantable hearing devices on the quality of life of very
young patients, their parents’ expectations and the well-
being of the family over time. A review of published
literature on available health-related, quality of life
instruments, hearing-health assessments and question-
naires used in the paediatric population and adminis-
tered via parent proxy was undertaken during the
development of this new measure. Specifically, an evalu-
ation of the most commonly assessed domains and evi-
dence of the corresponding sensitivity of the existing
measures for implant treatment effects was reviewed.
Published researchers of subjective scales used in the
hearing-implant field were consulted to help determine
the most relevant domains, content, and construct for
this tool [42-48]. The resulting 25-item parent-reported
questionnaire is divided into three sections; 1) Parental
Expectations, 2) Impact on the Family, and 3) Quality of
Life of the Child. The 25 questions cover the following
domains; self–reliance, wellbeing and happiness, social
functioning, general functioning, parental stress, and
family cohesion. The questionnaire has been piloted to
assess the feasibility and practicality of its use in
multiple cultural (i.e., English and Asian) and socio-
economic settings by parents and providers before
being introduced as a tool for use in the study. The
CuHI-QoL instrument is currently being validated by
researchers at the Department of Audiology and Speech
Therapy, University of Melbourne, Australia. The valid-
ation study includes parents of children with a hearing
impairment who use either hearing aids or cochlear
implants, and normal-hearing peers.
The Health Utilities Index - Mark III (HUI3) The HUI3
is a generic health status and health-related quality of
life questionnaire that was shown to be a sensitive
measure to demonstrate impact of medical treatments
over time across eight domains: vision, hearing, speech,
ambulation, dexterity, emotion, dexterity, cognition and
pain [48]. A number of studies demonstrate its effect-
iveness to determine the utility gained from implantable
hearing devices [49-51]. The HUI3 version used in this
study is suitable in children as young as age six years
[48]. A conservative approach was taken for the Coch-
lear P-IROS, making the questionnaire available for pa-
tients greater than or equal to age 10 years at the time
of enrolment. Validated translations have been licensed
and made available specifically for use in this study.
The Speech, Spatial and Qualities of Hearing Scale
(SSQ) The SSQ scale is a standardised questionnaire that
was shown to be a sensitive measure to demonstrate bene-
fits of bilateral versus unilateral hearing ability in a variety
of daily situations and a range of hearing abilities, acrossthree domains: speech, spatial and quality in adolescents
and adults [36]. Compared with the CAP-II, it provides
more finely detailed information about a patients’ auditory
performance in everyday situations, allowing for detailed
analysis. This version of the SSQ is available for comple-
tion by enrolled patients greater than or equal to age
10 years at the time of implantation.
The SSQ-Parents’ version (SSQ-P) The SSQ-P is avail-
able for response via parent proxy for enrolled patients
aged four to 10 years at the time of implantation. Based
on the original SSQ above, covering the same three
domains, it was modified and shortened for administra-
tion as a self-assessment tool for parental proxy follow-
ing observation of their child’s behaviour in various
listening environments in their daily lives, as considered
applicable [38]. The SSQ-P is not recommended for
parental proxy of children less than age four years, as
the developmental changes observed in these patients
may confound the judgment and, subsequently, the
measurement of intervention effect over time. The
reasons include difficulties associated with accurately
rating the performance of younger patients in questions
such as, “following a group conversation” [38]. In the
design of this questionnaire for use in non-English
speaking countries, a validated translation process was
employed (e.g., from English to Hindi and Hindi to
English). Necessary cultural adaptations were also made
as required (e.g., use of the term ‘motor scooter’ instead
of a ‘lawn mower’ in India) through personal communi-
cations with William Noble (University of New England,
NSW, Australia), the co-developer of the original SSQ.
Study hypotheses
Primary hypothesis
a. Post-implant performance for all patients on the
Categories of Auditory Performance-II (CAP-II) are
superior to pre-implant performance (baseline) and
show incremental improvement at each subsequent
post-implant assessment point (six months,
12 months, 18 months, 24 months, and annually for
up to five years) during the study.
Secondary hypotheses
a. Post-implant hearing ability for patients > 4 years of
age as assessed via the standardised Speech Spatial
and Qualities scale Parents’ version (SSQ-P) are
superior to their pre-implant hearing ability
(baseline) and show incremental improvement at each
subsequent post-implant assessment point (six months,
12 months, 18 months, 24 months, and annually
thereafter for up to five years) during the study.
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using binaural hearing/stimulation is superior to that
of patients using unilateral hearing/stimulation at
each post-implant evaluation point (six months,
12 months, 18 months, 24 months, and annually
thereafter for up to five years) during the study as
measured by assessments of the:
i. Categories of Auditory Performance – II (CAP –II)
scale for all patients
ii. Speech Spatial and Hearing Qualities Parents’
version (SSQ-P) scale
iii. Post-implant, aided hearing-threshold levelsTertiary hypotheses
a. Post-implant assessment of quality of life for the
patient and family via the CuHI-QoL questionnaire
as assessed by the parent or caregiver are superior
to quality of life assessed at baseline (pre-implant)
and show incremental improvement at each
subsequent post implant evaluation time point
(six months, 12 months, 18 months, 24 months,
and annually thereafter for up to five years) during
the study.
b. Patients who begin mainstream school during the
study enter at an age-appropriate time.
c. The proportion of patients who are participating in
mainstream school with no additional support is
higher than the proportion of patients in other
categories of school placement.Study implementation
Data management
The Cochlear P-IROS registry is managed by an expe-
rienced, third-party database service provider based in
Gembloux, Belgium. The data is stored centrally in
an externally hosted, electronic data capture (EDC)
platform that is compliant with the standards of the
International Conference on Harmonisation – Good
Clinical Practice (ICH-GCP) and the US FDA-21-Code
of Federal Regulations-Part 11 (FDA-21-CFR-part-11)
[52-54]. The Cochlear P-IROS registry protocol ad-
heres to published guidelines for the design and imple-
mentation of patient-outcomes registries [33,55]. The
Cochlear P-IROS electronic, web-based platform is
currently available in five languages; English, Manda-
rin, Korean, Japanese and Russian. The minimum
hardware and software requirements for implementa-
tion of the registry include having an internet connec-
tion allowing normal and secured communications as
well as Adobe Reader Version 8.0 or higher installed
(Note: Safari 5.1 or later requires Adobe Reader 10.1.4
or higher.)User access
Access to the information collected by the Cochlear
P-IROS registry is limited by functionality to a confined
number of users at the study site and Cochlear Limited,
as defined in Table 2. Each site may have up to four
types of investigators including one chief investigator
and one or more of an unlimited investigator, limited
investigator and a study nurse. The unlimited versus
limited nature of an investigator’s responsibility is re-
lated to their capacity to view, edit and download all of
the site’s patient details versus only the details of the
patients they personally enrolled into the system. Data
may be viewed and downloaded (but not edited) by the
global and country level project leaders of the Cochlear
P-IROS. The database administrators from the third-
party EDC provider of the Cochlear IROS platform may
also gain access to view data and troubleshoot, should
problems arise. To gain user access, a user must complete
the IROS User Request Registration Form. User access
registration forms are available upon request through con-
tacting the global project leaders of the study (GS, JW and
TVA) at CochlearIROS@cochlear.com.
Data privacy and intellectual property
All clinics will have ownership rights for their site’s data
and the flexibility to operate under their own local pro-
cesses or regulations around data collection, privacy
and maintenance of patient records. In Australia, all
participating clinics must obtain ethical approval for the
Cochlear P-IROS from a legislated Human Research
Ethics Committee (HREC), who will assess the study’s
protocol and documents for breach of privacy stan-
dards. Under the Australian Privacy Act, the data col-
lected and stored by the Cochlear P-IROS registry is not
classed as, “personal information”, as a patient’s identity
is preserved within the database, i.e., no identifiable per-
sonal data is collected in any of the evaluation forms
administered as part of the study. The Cochlear P-IROS
registry is also listed on the Australia New Zealand
Clinical Trials Registry, a public database for clinical re-
search in humans that is globally recognised [56].
Electronic case report forms
The logical framework of the Cochlear P-IROS registry
is set-up as a series of evaluation tools in the format of
eCRFs that must be completed through data entry via
the electronic platform according to the study’s evalu-
ation schedule. The evaluation schedule highlighting
the required and optional assessments is illustrated in
Table 1. Paper copies of the eCRFs may also be down-
loaded and printed from the study platform at any
time, ultimately for completion, and storage, ideally in
the patient’s clinic file, until data entry online can be
undertaken for electronic data capture.
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translated into 22 languages spoken in China, Japan,
Korea, India, Middle East, Taiwan, Turkey, South Africa,
South East Asia, Europe and South America and Russia.
Data entry
The Cochlear P-IROS registry may complement man-
agement of patients at clinics including their routine
clinical follow up. A clinician or another approved per-
son at the clinic could enter the data into the Cochlear
P-IROS platform. Investigators participating in the regis-
try will have access to real-time patient data updates as
well as automated summary reports through the use of
their confidential, system-allocated password.
For investigators, automated email reminders notifying
follow-up times for individual patients will be sent two
months before the evaluation is due. If participating
families wish to opt-out of the study, completion of an
End of Study form will be required.
For parents/caregivers who have elected and agreed on
the patient informed consent form to respond directly
on-line, an automated email reminder will be sent two
months prior to the next follow-up evaluation for their
child, and on the day of the scheduled follow-up. If a
parent/caregiver do not respond and complete the rec-
ommended evaluations for a particular time-point, the
clinician will be subsequently notified by email. A notifi-
cation will be sent to the clinician, once the parent has
completed their data entry for that time-point.
Data outputs
The Cochlear P-IROS web interface facilitates centre-
specific, automated summary reports on the number of
patients recruited to-date, their age at implantation,
number and types of implants and outcomes (i.e.,
mean CAP-II, mean SSQ-P and mean CuHI-QoL).
Country and global summaries across these measures
are also provided to support national and international
benchmarking of performance. Routine newsletters and
reports on the study progress and other updates are to be
developed by the global administrators and sent to the
participating centres.
Data monitoring
There will be no routine onsite monitoring undertaken
of the data entered. Participating clinics are not asked to
store paper documents as source documents for data
entered online. Hence, cross checks between data
entered and source data is not possible. Online random
spot-checks will be conducted on five percent of the
data entered quarterly at each participating Cochlear
P-IROS clinic by the global administration team.
The platform has been designed with inherent checks-
of-response fields entered on eCRFs and automaticallypending response types. The vast majority of responses
on all forms are multiple choice, check box, radio but-
tons or pull-down response options to facilitate entry
and reduce entry error. Minimal free-text response fields
are included. The electronic registry platform operating
the Cochlear P-IROS contains an inherent audit trail to
trace all amendments made with each form, the investi-
gator making the change and when changes are made.
To avoid unnecessary changes, eCRFs are automatically
locked upon access and data entry into the correspond-
ing form at a subsequent assessment interval. Manual
unlocking of these forms can be requested by the clin-
ician to the Cochlear P-IROS global administrator.
Statistical analysis
A proposal for the statistical methods and data analysis
plan for the assessment of Cochlear P-IROS hypotheses
created by a consultant statistician is available as a
separate report upon investigator’s request. Prospective,
longitudinal studies, such as the Cochlear P-IROS, are
especially powerful due to the repeated measures on par-
ticipants. As such, relatively low numbers of observations
may be adequate for most tests. A sample size of n = 50
was considered sufficiently sensitive to measure implant
treatment effects assessed by the CAP-II, based on pub-
lished literature. Current publications on paediatric
cochlear implants lack sufficient detail on the SSQ-P or
SSQ to generate an accurate power calculation for the
sample sizes needed to find significant differences or
changes; whilst CuHI-Qol is a completely novel out-
come measure and, therefore, a sample size calculation
is not currently possible.
It is also not possible to determine the actual number
of patients that will be registered with the Cochlear
P-IROS over time, as participation in the Cochlear
P-IROS is voluntary for the clinic and the parent/
caregiver/patient. Additionally, the parent/caregiver/
patient may also cease to participate in the registry at
any time. Nevertheless, the design of the database does
not pose any constraint on the number of patients that
may be enrolled over time, as it was developed with the
aim to sustain data collection in the long-term. Large
scale enrolment of patients in the range from 100 to
1000 or more on an annual basis is expected.
Discussion
The Cochlear P-IROS provides a unique opportunity for
improving the evidence base relating to outcomes achieved
by patients with a permanent hearing impairment using
implantable hearing devices. It removes barriers to partici-
pation from non-English speaking clinicians and patients
by offering an easy-to-access, secure web platform with
multiple language options and automated reports to
support benchmarking activities. The registry is designed
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comes data from newly implanted patients who are pre-
sented for routine intervention.
The Cochlear P-IROS web interface, as well as patient
forms, have been translated into multiple languages in
order to enable cross cultural data collection and subse-
quently cross cultural application of the interpreted out-
comes. Thereby, the study reduces the potential risk of
selection bias that may arise from exclusion of patients
with a non-English speaking background. The Cochlear
P-IROS design also minimises potential bias from recall
errors, with a recall memory period of four weeks
requested at each evaluation interval [57]. The authors,
however, acknowledge that there may be a risk of emo-
tional bias for the baseline evaluation time point. This is
because the evaluation takes place part way through the
two-part fitting of an implantable hearing device; that is,
after the surgical placement of the internal implant but
before activation of sound, with the fitting of the exter-
nal sound processor.
The registry addresses industry-wide concerns around
a lack of language-independent, standardised outcome
measures for paediatric recipients of implantable hearing
devices. To date, the wide variety of language-based,
auditory-related outcome measures utilised in this pa-
tient population hinders effective meta-analysis [19].
Through the development of a new quality of life instru-
ment, the CuHI-QoL, and the use of a range of standar-
dised outcome measures (SSQ-P and CAP-II), Cochlear
P-IROS aims to provide a homogeneous set of data for
the comparison of benefit of implantable hearing devices
for considerably larger numbers of patients that are
more representative of the treated population.
The advantages of using questionnaires for subjective
assessment is that it allows for a view to the benefits
obtained post-implantation through the patient’s eyes or
in the eyes of their parents, specifically demonstrating
hearing benefits and additional hearing-related benefits.
A further advantage, not specifically addressed in this
paper is the ability to use validated translations of such
questionnaires for collection and collation of qualitative
patient-reported benefits across different languages, both
pre and post-implant, longitudinally [19,9,39]. Compari-
son of auditory benefit data assessed and reported using
local speech audiometry measures is both challenging, in
view of the differences in materials and methods, and not
recommended where equivalency in materials and mea-
surements is unknown. The Cochlear P-IROS approach
could foster not only consistency of data collected but also
encourage the reporting of consistent evaluation methods.
This makes it one step closer to the possible availability
of published meta-analyses of collective standardised
outcomes from patients using implantable hearing
devices, which could potentially be used by regulators,health technology assessors and health service provision
decision makers.
The Cochlear P-IROS may preclude the need for
large local capital investment to design and implement a
multi-centre web-based registry. The study provides the
grounds for various hearing implant clinics to develop
and own their own set of patient profiles, outcomes data
and accordingly pursue their own research interests
which may lead to scientific publications. Collaborative,
multi-centre publications are especially encouraged to
combine data collection efforts from different investiga-
tors, which may strengthen the potential power of the
data reported and the interpretation of the conclusions
drawn. The Cochlear P-IROS registry, therefore, provides
a cost-effective method for interested parties to establish
and invest in the outcomes of patients using implantable
hearing devices in the long term, in a clinically feasible,
broadly consistent and practically sustainable manner.
Additional file
Additional file 1: Children using Hearing Implants Quality of Life
(CuHI-QoL) questionnaire. This is a new quality of life instrument
developed to assess quality of life of patients using implantable hearing
devices via parent proxy. Its aim is to assess the impact of hearing
implant devices on the quality of life of very young patients, their parents’
expectations and the wellbeing of the family, over time.
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